PharmaTher Secures FDA Meeting for Ketamine Drug
Company Announcements

PharmaTher Secures FDA Meeting for Ketamine Drug

Story Highlights

PharmaTher Holdings Ltd (TSE:PHRM) has released an update.

PharmaTher Holdings Ltd. has secured a meeting with the FDA to address a complete response letter regarding its ketamine drug application, aiming to resolve minor deficiencies. The company is focused on meeting FDA guidelines to help alleviate the ongoing ketamine shortage in the U.S., where ketamine has been in short supply since 2018.

For further insights into TSE:PHRM stock, check out TipRanks’ Stock Analysis page.

Related Articles
TheFlyPharmaTher granted post-CRL clarification meeting request by FDA
TipRanks Canadian Auto-Generated NewsdeskPharmaTher Faces FDA Setback for Ketamine Drug
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App